- Home
- PIII vs XLO Comparison
PIII vs XLO Comparison
Compare PIII & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- XLO
- Stock Information
- Founded
- PIII 2015
- XLO 2016
- Country
- PIII United States
- XLO United States
- Employees
- PIII N/A
- XLO N/A
- Industry
- PIII Medical/Nursing Services
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- XLO Health Care
- Exchange
- PIII Nasdaq
- XLO Nasdaq
- Market Cap
- PIII 37.5M
- XLO 37.9M
- IPO Year
- PIII N/A
- XLO 2021
- Fundamental
- Price
- PIII $0.21
- XLO $0.93
- Analyst Decision
- PIII Buy
- XLO Buy
- Analyst Count
- PIII 3
- XLO 1
- Target Price
- PIII $2.38
- XLO $4.00
- AVG Volume (30 Days)
- PIII 1.3M
- XLO 10.6M
- Earning Date
- PIII 03-27-2025
- XLO 03-31-2025
- Dividend Yield
- PIII N/A
- XLO N/A
- EPS Growth
- PIII N/A
- XLO N/A
- EPS
- PIII N/A
- XLO N/A
- Revenue
- PIII $1,476,630,000.00
- XLO $4,620,000.00
- Revenue This Year
- PIII $21.45
- XLO N/A
- Revenue Next Year
- PIII N/A
- XLO $558.79
- P/E Ratio
- PIII N/A
- XLO N/A
- Revenue Growth
- PIII 25.38
- XLO N/A
- 52 Week Low
- PIII $0.17
- XLO $0.55
- 52 Week High
- PIII $1.20
- XLO $1.93
- Technical
- Relative Strength Index (RSI)
- PIII 49.40
- XLO 48.99
- Support Level
- PIII $0.20
- XLO $0.97
- Resistance Level
- PIII $0.25
- XLO $1.22
- Average True Range (ATR)
- PIII 0.02
- XLO 0.14
- MACD
- PIII 0.00
- XLO 0.03
- Stochastic Oscillator
- PIII 46.32
- XLO 28.04
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).